PATENT APPLICATION DOCKET NO.: 3033.1000-008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Darrell H. Carney

Application No.:

10/050,611

Group Art Unit: 1653

Filed:

January 16, 2002


Examiner: Robert A. Wax

Confirmation No.: 6599

Title:

METHODS OF THERAPY WITH THROMBIN DERIVED PEPTIDES





Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I his I	nformation Disclosure Statement is submitted:	
[]	under 37 CFR 1.129(a), or	
	(First/Second submission after Final Rejection)	
[]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including CPA, or a Request for Continued Examination).	ga
[X]	under 37 CFR 1.97(c) together with either:	
	[] a Statement under 37 CFR 1.97(e), as checked below, or	
	[X] a \$180.00 fee under 37 CFR 1.17(p), or	
	(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)	0050611
ſΊ	under 37 CFR 1.97(d) together with:	100

a Statement under 37 CFR 1.97(e), as checked below, and

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

a \$180.00 fee under 37 CFR 1.17(p), or

r 1	under	37	CFR	1 97	٦
	under	וכ	CIT	エ・フィ	(1)

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

07/08/2004 MBLANCD 00000008 10050611

State	ment Un	<u>ider 37 (</u>	<u>CFR 1.97(e)</u>				
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or						
[]	comm knowl in the	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
State	ment Un	der 37 C	CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29	, 2000			
[]	comm was n	unication of receiver	information contained in the Information Disclosure Statement was cited in a on from a foreign patent office in a counterpart application and this communicated by any individual designated in § 1.56(c) more than thirty days prior to the information Disclosure Statement.				
[X]	Enclo	sed here	ewith is form PTO-1449:				
	[X]	Copies	s of the cited references (AN, AO, AP, AX3 and AY3) are enclosed.				
		[]	Since this application was filed after June 30, 2003, copies of issued U.S. pat and published U.S. applications are not required and are not being provided.	ents			
	[]	Applic	s of the cited references are enclosed except those entered in prior application, cation No. [], to which priority under 35 U.S.C. 120 is claimed. [The eation contains copies of the cited references.]	U.S. rlier			
	[]	The list	sted references were cited in the enclosed International Search Report in a erpart foreign application.				
	[]		concise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:]			
		[]	the explanation provided on the attached sheet.				
		[]	the explanation provided in the Specification.				
		[]	submission of the enclosed International Search Report.				
		[]	submission of the enclosed English-language version of a foreign Search Repand/or foreign Office Action.	ort			
		[]	the enclosed English language abstract.				

[]	A	.pplic	ant requests that the following n	on-published pending applic	cations be considered:
Examiner's	;				
			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			Examiner	Date	_
	[]	A copy of each above-cited app	olication, including the curre	nt claims, is enclosed.
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	olication, including the current on, U.S. Application No. [nt claims, is enclosed, except], to which priority under
The E	xar nce	niner s wei	is requested to return a copy of re considered with the next offic	the above list of pending appe communication.	olications indicating which
It is re	qu	ested	that the information disclosed h	erein be made of record in the	nis application.
Metho	d c	of pay	ment:		
[X]			ek for the fee noted above is encl panying Amendment. A copy of		luded in the check with the
[]	Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.				
[X]	P	lease	charge any deficiency in fees an	d credit any overpayment to	Deposit Account 08-0380.
			R	Respectfully submitted,	
			H	IAMILTON, BROOK, SMIT	ΓΗ & REYNOLDS, P.C.
			, B	Helen Lee Registration No.: 39,270 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	

Concord, MA 01742-9133 Dated: July 2, 2004

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

July 2, 2004

Use several sheets if necessary)

ATTORNEY DOCKET NO. 3033.1000-008

APPLICATION NO. 10/050,611

FIRST NAMED INVENTOR Darrell H. Carney

FILING DATE
January 16, 2002

EXAMINER
Robert A. Wax

CONFIRMATION NO. 6599

GROUP 1653

MADEMARK	F	OREIGN PATENT D	OCUMENTS		-
HALL	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSL YES	ATION NO
AN	WO 94/25056	11/10/1994	Washington University		
AO	WO 99/53943	10/28/1999	Angio-Genix, Inc.		
AP	WO 00/24412	05/04/2000 °	Ludwig Institute for Cancer Research		
					
					· · · · · ·
				,	
			-		

EXAMINER	DATE CONSIDERED

				Sheet 2 0
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3033.1000-008		LICATION NO. '050,611	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 2, 2004	FIRST NAMED INVENTOR Darrell H. Carney FILING DATE January 16, 2		2002	
July 2, 2004 (Use several sheets if necessary)	EXAMINER Robert A. Wax	CONFI 6599	RMATION NO.	GROUP 1653
. F	-			

		,
TRAD	EMAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AX3	Tsopanoglou, N.E., and Maragoudakis, M.E., "On the Mechanism of Thrombin-induced Angiogenesis," J. Biol. Chem., 274(34):23969-23976 (1999).
	AY3	Coleman, C.L., et al., "Systemic Injection of Thrombin Peptide TP508 Mitigates Angioplasty-related Restenosis in Hypercholesterolemic Rabbit Iliac Arteries," Abstract LB14, Presented at the Experimental Biology 2001 Meeting (Orlando, Florida).
L I		

EXAMINER	DATE CONSIDERED
	·
ll .	